Kalohexis Presents Phase 2 Cachexia Trial Design at AACR 2026
Event summary
- Kalohexis will present a poster on the Phase 2 Paradox trial of mifomelatide for cancer cachexia at AACR 2026.
- The trial, initiated in Q2 2025 by Endevica Bio and now run by Kalohexis, evaluates safety, tolerability, and efficacy in advanced colorectal cancer patients.
- Primary endpoints include changes in body weight, adverse events, and lab/vital sign abnormalities; secondary endpoints track appetite and quality of life.
The big picture
Kalohexis is positioning itself as a leader in metabolic disease care by targeting both obesity and cancer-related cachexia through the melanocortin system. The Paradox trial represents a critical step in validating mifomelatide’s potential, while broader industry trends favor precision therapies for metabolic disorders. Success here could accelerate Kalohexis’ path to commercialization in a competitive oncology space.
What we're watching
- Trial Execution
- Whether the Paradox trial can deliver meaningful weight stabilization and quality-of-life improvements in cachexia patients.
- Regulatory Pathway
- How AACR feedback may influence future regulatory discussions for mifomelatide.
- Pipeline Momentum
- The pace at which Kalohexis advances its dual obesity and cachexia pipeline.
Related topics